Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of a Combination of 5-azacitidine Followed by Lenalidomide in High-risk MDS or Relapsed/Refractory AML Patients With Cytogenetic Abnormalities Including -5 or Del(5q)

NCT00923234 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT00923234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00923234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of a Combination of 5-azacitidine Followed by Lenalidomide in High-risk MDS or Relapsed/Refractory AML Patients With Cytogenetic Abnormalities Including -5 or Del(5q)
Lead sponsor
Technische Universität Dresden
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2009
Completion date
July 31, 2012
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, myelodysplastic syndromes